BiotechTube
HasenTech

HasenTech

San Diego, United States· Est.
hasentechbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

HasenTech is a private, preclinical-stage biotech developing HT-01, a novel exopolysaccharide (EPS) therapy to make bone marrow transplants safer by preventing Graft-versus-Host Disease (GvHD). The company's foundational IP is based on research from the University of Massachusetts, with a patent issued in 2019. Led by a seasoned team with a prior successful exit (Hematech), HasenTech aims to address a significant unmet need in transplant medicine and expand into broader inflammatory and autoimmune conditions.

Graft-versus-Host Disease (GvHD)Inflammatory DiseaseAutoimmune Disease

Technology Platform

Exopolysaccharide (EPS) derived from Bacillus subtilis, a natural sugar polymer with immunomodulatory properties that induces anti-inflammatory M2 macrophages and suppresses immune responses.

Opportunities

Reducing GvHD could expand the eligible pool for bone marrow transplants from ~50,000 to an estimated 200,000 procedures annually, creating a significant market expansion opportunity.
Success in GvHD provides a clinical proof-of-concept to rapidly expand the EPS platform into larger inflammatory disease markets like IBD and Crohn's disease.

Risk Factors

The lead program is in preclinical development, carrying high risk that animal efficacy/safety will not translate to humans.
The company has not disclosed any funding, posing a major resource risk for advancing to clinical trials.
It must compete in an established GvHD market with existing therapies and novel agents in development.

Competitive Landscape

The GvHD prophylaxis and treatment market includes corticosteroids, calcineurin inhibitors, mTOR inhibitors, and newer JAK inhibitors (e.g., ruxolitinib). HasenTech's novel EPS mechanism would need to demonstrate differentiated efficacy or a superior safety/tolerability profile against these standards and other novel approaches in development.

More companies in Small Molecule Drugs →More companies in United States →